News & Views
Partnership to develop perfusion process for AAV production
Oct 14 2024
A £1.4m Innovate UK Transforming Medicines Manufacturing (TMM) Programme grant has been awarded to the Cell and Gene Therapy catapult (CGT Catapult), strategic partner Pharmaron Biologics (UK) Ltd and Complement Therapeutics, a developer of therapeutics for complement-mediated diseases, to develop a perfusion process that will improve gene therapy production.
Adeno-associated virus (AAV) vectors are used in a number of approved gene therapies that target rare conditions and the aim of the two year partnership is to target higher-prevalence conditions. Perfusion processing enables the continuous exchange of fresh culture medium and the removal of waste. This allows for AAV to be produced from a higher density of cells, over extended periods of time, reducing production costs.
Matthew Durdy, Chief Executive of the Cell and Gene Therapy Catapult, said: “AAV is a crucial element in many gene therapies yet there are currently no clinically approved AAV products manufactured using perfusion technologies. Working with experts at Pharmaron and Complement Therapeutics, this project offers a valuable opportunity to unlock the benefits of this manufacturing process. This aims to help make gene therapies more affordable to healthcare systems and ensure that sufficient volumes of AAV can be produced to meet an increase in demand.”
Derek Ellison PhD, VP Biologics Services Europe at Pharmaron Biologics (UK) Ltd, said: “While perfusion has been successfully applied to intensify production and improve manufacturability and process economics for more traditional biologics such as recombinant proteins, there are few, if any, successful applications for gene therapies. Leveraging the advanced processing and product characterisation capabilities of Pharmaron’s Liverpool site, allied with the technologies and expertise of Complement Therapeutics and the CGT Catapult, this project aims to make a major breakthrough in this area, to the benefit of patients and customers.”
Rafiq Hasan, Chief Executive Officer of Complement Therapeutics, said: "We are excited to collaborate with Pharmaron and the CGT Catapult on this project. Developing a perfusion process for AAV production holds significant promise for advancing our pipeline of treatments for complement-mediated diseases. This initiative not only represents a technological leap forward but also aligns with our mission to address high unmet clinical needs and ultimately improve patient outcomes.”
More information online
Digital Edition
LMUK 49.7 Nov 2024
November 2024
Articles - They’re burning the labs... Spotlight Features - Incubators, Freezers & Cooling Equipment - Pumps, Valves & Liquid Handling - Clinical, Medical & Diagnostic Products News...
View all digital editions
Events
Nov 11 2024 Dusseldorf, Germany
Nov 12 2024 Cologne, Germany
Nov 12 2024 Tel Aviv, Israel
Nov 18 2024 Shanghai, China
Nov 20 2024 Karachi, Pakistan